An open label, multi-centre, phase III, subject initiated safety study of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] in treatment of recurrent herpes simplex labialis in adolescents,
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2011
At a glance
- Drugs Aciclovir/hydrocortisone (Primary)
- Indications Herpes labialis
- Focus Adverse reactions
- 26 Oct 2010 Results presented as a poster at the American Osteopathic Association's (AOA) 115th Osteopathic Medical Conference and Exposition.
- 19 Mar 2008 Results from the phase III program reported in a Medivir media release.
- 13 Feb 2008 Results from the Lipsovir phase III program are expected in late March or early April 2008.